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ABSTRACT 1 
Background Observational research is increasingly important in clinical decision-making. Opt-out 2 
consent has been proposed as a more practical way to obtain participants’ consent for such. We 3 
evaluated patients’ views on opt-out consent for observational research by identifying perceived 4 
benefits and barriers.  5 
Methods Following a systematic literature review of research on participants’ perspectives on opt-6 
out consent, we conducted a focus group interview with oncological patients and their family 7 
members. 8 
Results We identified thirteen articles detailing perspectives on opt-out consent. Perceived 9 
advantages included benefitting medicine and future generations. These findings were confirmed 10 
in our focus group. The main reported barriers to opt-out consent are concerns regarding privacy 11 
and the sharing of data with third parties. Participants also demonstrated concerns on insufficient 12 
education on opt-out consent. 13 
Conclusions Participants demonstrated willingness to participate in observational studies utilizing 14 
opt-out consent. Special focus should be placed on outlining existing safeguards in research.  15 
  16 
Key points 17 
• Our results include a comprehensive systematic review of the literature following the 18 
PRISMA guidelines.  19 
• Additional qualitative data was obtained from a focus group, an experienced research 20 
consumer panel, and an existing real world evidence database.  21 
• Participants demonstrated willingness to participate in studies utilizing opt-out consent, 22 
however this was impeded by some key concerns.  23 
• Special focus should be placed on outlining the existing safeguards in research.  24 
• Improving public opinion on studies using presupposed consent could lead to decreased 25 
selection bias.  26 
• Nonetheless, the scope for opt-out consent has been further limited by the provisions of 27 
the General Data Protection Regulation (GDPR) which came into force in May 2018. 28 
 29 
Reflective questions 30 
• How do patients perceive an opt-out consent procedure? 31 
• What are current barriers for patients to approve of opt-out consent? 32 
• How does the interpretation of the General Data Protection Regulation affect the use of 33 
opt-out consent in academic research? 34 
  35 
INTRODUCTION 36 
The significance of providing personalized care to patients is increasingly recognised in 37 
current medical practice. An invaluable tool to this purpose is real-world evidence (RWE). RWE 38 
refers to data, mostly observational, collected in contexts other than typical research settings, 39 
such as during routine clinical care.(1, 2) Unlike other forms of data collection, including 40 
randomised controlled trials, RWE has greater external validity and better applicability to 41 
underrepresented patient groups due to decreased selection bias.(1, 3-5) Hence, the use of RWE is 42 
permissive to clinicians more equitably addressing the needs of singular patients in real-world, 43 
day-to-day contexts. 44 
Yet maintaining the benefits of RWE can be challenging, as much validity can be lost whilst 45 
obtaining participants’ consent. Selection bias is bound to occur when participant consent is 46 
secured via the currently widespread opt-in recruitment strategy, as has been demonstrated in 47 
various studies.(6-9) It can be argued, however, that when the collection of observational RWE 48 
poses remote risks of harm to the participants involved, opt-out consent can be utilised.(10-12) 49 
Opt-out systems rely on implicit consent, where willingness to participate is tacit or 50 
presumed and can be retracted by active objection.(13) These generate more complete data, with 51 
less biased samples and improved response rates, as compared to opt-in consent strategies.(9, 14, 52 
15) Moreover, opt-out consent is preferable in large cohorts, where other strategies could be too 53 
costly or impractical to enact.(12, 16-18) However, it is unclear whether public opinion 54 
unequivocally supports opt-out. Existing studies demonstrate the public holds varying views about 55 
which process of consent is ideal.  56 
Hence, the aim of this study was to explore cancer patients’ opinions of opt-out consent 57 
for the secondary use of their health records. Following a systematic review of the literature, we 58 
conducted a focus group with oncological patients and their relatives, furtherly exploring their 59 
opinions and concerns. In addition, we assessed the experience of opt-out consent in real-time 60 
clinical practice in our institution. 61 
 62 
METHODS 63 
Systematic literature review 64 
This systematic review was conducted following the PRISMA statement for completing  65 
systematic reviews and meta-analyses (19).  A computerised literature search of the Ovid 66 
MEDLINE database to identify full text and abstracts published between 1946 and November 21st 67 
2017 was performed.  The following search strategy was used: Opt-out and (consent or view* or 68 
perspective* or ethic* or attitude*) and (research or biobank or trial or health record* or medical 69 
record*). All references of the selected articles were checked, including hand searches.  70 
The final articles were chosen based on the following set of inclusion criteria: the publication 71 
pertained to a patient-focused study which clearly defined opt-out; the manuscript was published 72 
in English.  The literature review and data collection was conducted by LC and reviewed by MVH.  73 
Initially, titles were reviewed to assess whether they met inclusion criteria.  Titles that 74 
indicated the study met these criteria progressed to an abstract review.  Upon inclusion after this 75 
step, the full manuscript was thoroughly checked to evaluate inclusion and exclusion criteria.  76 
Figure 1 provides more detailed information regarding the exclusion process. The following details 77 
were recorded for each study: author, year of publication, country where study was undertaken, 78 
number of participants, and method of data collection.   79 
  80 
Focus group participants and setting 81 
Patients being treated at Guy’s Cancer Centre (London, UK) for urological tumours, breast 82 
or lung tumours were recruited to participate in a focus group by invitational flyers handed out 83 
whilst visiting the Centre for routine appointments. Family members and relatives were also 84 
encouraged to participate. We aimed to have at least 10 participants as to ensure all relevant 85 
themes and opinions would be picked up (20). Participants were introduced to the purpose of the 86 
focus group and asked to complete an anonymous demographic questionnaire. Informed consent 87 
was obtained for the recording and processing of the interview. The focus group was conducted 88 
by a research nurse and two note-taking assistants. Initially, broad questions about participants’ 89 
previous exposure to research were discussed. Subsequently, a brief presentation on selection 90 
bias and opt-out research with secondary use of medical records was held. This presentation 91 
illustrated: 1) the mechanism of opt-in consent; 2) how selection bias can arise; 3) the mechanism 92 
of opt-out consent; 4) the advantages and disadvantages of opt-out consent, as compared to opt-93 
in. Participants were asked to illustrate their reactions to an opt-out consent methodology, 94 
discussing the favourable aspects of such and their concerns. The discussion was framed on a set 95 
of questions developed on the common themes identified in the literature review (Table 1), 96 
however participants were encouraged to voice any other relevant ideas and free discussion 97 
amongst the group was supported.  98 
Further validation for the focus group findings was also sought from the South East London 99 
Consumer Research Panel on Cancer (SELCRP). This is a group of patients, patient advocates and 100 
researcher representatives providing advice to researchers on study proposals and other topical 101 
issues. The SELCRP received the same brief presentation on selection bias and opt-out research as 102 
the focus group. Subsequently, representatives were encouraged to voice their views on 103 
presupposed consent for medical research.   104 
 105 
Data analysis  106 
 The focus group was fully audio recorded and transcribed verbatim. The resulting 107 
transcript was analysed thematically, coding topics mentioned with the NVivo 11 software (QRS 108 
international, 2017).(21) Emergent themes were identified and grouped into broader statements, 109 
which were furtherly elucidated in view of the literature review findings.  110 
 111 
Institutional experience of opt-out consent 112 
 Consecutive patients entering an ethically approved opt-out clinical database for patients 113 
with cancer of the upper gastro-intestinal tract at our institution were observed over a one year 114 
period for tolerability and withdrawal of consent (REC 17/NW/0377). Information regarding the 115 
use of data, access to data and the process for opting-out was made available to all patients as 116 
standard. 117 
 118 
Patient and Public Involvement 119 
As outlined above, patients and public were at the centre of this work. The study aimed to 120 
identify how opt-out can be used in future to conduct studies based on anonymised, routinely 121 
collected data. We worked with our patient support groups to identify relevant research questions 122 
and themes and also involved them in our interpretation of the findings from the systematic 123 
literature review. Hence, we have full PPI support for the findings and write-up of the current 124 
manuscript. The published manuscript will be shared with the wider patient support network at 125 
our hospital.   126 
 127 
RESULTS 128 
Literature review 129 
 The PRISMA flow diagram in Figure 1 shows the 367 unique hits yielded from our search. 130 
Titles and abstracts were screened. Twenty-nine titles meeting the criteria were reviewed in their 131 
full text by two authors. Additional relevant studies were identified hand searching bibliographies 132 
and utilising the “similar articles” function in PubMed. The resulting 13 papers included 5 studies 133 
focussing on opt-out consent for the institution of biobanks,(22-26) whilst 8 addressed opt-out 134 
consent for the secondary use of medical records.(27-34)  135 
 Characteristics of included studies are collated in Table 2. Common themes identified in 136 
the literature review were subdivided into statements of support versus concern on opt-out 137 
consent, and are summarised in Tables 3 and 4. As this review included qualitative studies, a 138 
quantitative synthesis was not performed. 139 
 140 
Support of an opt-out consent strategy 141 
Ten of the thirteen studies included in this review specifically reported participants 142 
supporting opt-out consent, acknowledging its importance in progressing medical knowledge.(22, 143 
25-32, 34) Other rationales for support included providing benefit to others, to self or family and 144 
to other patients with the same disease.(22, 24) 145 
Seven studies noted participants support opt-out consent specifically because of their trust 146 
in researchers or in the research institution.(22-24, 28, 30-32) In such cases, participants were 147 
confident the sensitive data collected from opt-out studies would be effectively protected.  148 
 Participants recognised the convenience of opt-out consent, both from the viewpoint of 149 
study subjects and of the organising researchers. In one paper, participants preferred opt-out over 150 
other forms of consent, as it eliminates the need for redundant consenting for repeated 151 
studies.(25) From researchers’ perspectives, three studies recognised that opt-out systems are 152 
more cost- and time- effective than other forms of consent, thus facilitating research.(25-27) 153 
 Participants stated that presupposing consent is acceptable as long as certain safeguards 154 
are present. Centrally, participants accepted opt-out systems insofar as the choice of opting-out is 155 
clear, and possible at all times.(23, 25, 27, 33) This was argued to allow free judgement, whilst 156 
providing flexibility for subjects changing opinion throughout the study. Also, participants 157 
requested the anonymisation of their personal data.(23, 30, 32) Two studies reported desire for 158 
the provision of an independent review group functioning as a “watchdog” protecting subjects’ 159 
interests.(27, 33) 160 
 161 
Concerns about an opt-out consent strategy 162 
The key concerns on opt-out consent reported by the literature regard privacy and its 163 
protection. Participants were troubled that presupposing consent could entail loss of privacy, 164 
especially due to possible breaches in confidentiality.(22, 24, 26-33) Moreover, three papers 165 
reported scepticism on the security measures present to protect the confidential data 166 
collected.(30, 31, 33) 167 
 Studies recorded adversity towards third parties’ use of data from opt-out research. 168 
Participants disapproved of commercial data sharing, being concerned by use of data for purposes 169 
other than benefitting patients and by third parties’ privacy policies.(28, 32, 33) Participants were 170 
also concerned with inappropriate use of data by parties such as banks, mortgage and insurance 171 
companies.(26, 27, 31-34) Studies reported concerns that inappropriate use of collected data 172 
could trigger discrimination of particular ethnic and religious groups.(30, 31, 33) 173 
 Finally, the literature registered apprehension on insufficient information being provided 174 
to research participants. Nine papers reported concern for inadequate details given prior to 175 
formulating consent, especially regarding the purpose of the research performed and on who is 176 
granted access to patients’ data.(22, 26-29, 31-34) Concern for peers not reading or being able to 177 
comprehend the information provided was also noted.(26, 29, 32, 33) Additionally, one study(29) 178 
reported worry on possible difficulties in indicating the will to opt-out, and one disapproved the 179 
passivity of the consent obtained in opt-out systems.(26) 180 
 181 
Focus group 182 
Thirteen patients and carers took part in our focus group. The demographics of 183 
participants are summarised in Table 5. Upon questioning, all participants had some 184 
understanding of medical research and its importance, most having either been approached for or 185 
taken part in research at least once. Nonetheless, prior to the presentation held, only one 186 
participant could explain what opt-out consent entails, reflecting that most of the public has been 187 
exposed to opt-in consent exclusively, due to its widespread use as the ethical gold standard in the 188 
healthcare context. Indeed, following the presentation many participants posed questions 189 
regarding the mechanisms of presupposed consent applied to secondary use of their records. 190 
When participants’ understanding of opt-out consent was clarified, a broad support for it was 191 
registered (Table 6). 192 
 To facilitate analysis, participants’ perceptions on opt-out consent were broadly 193 
categorised into statements of either support or of concern, with representative quotations 194 
reported in Table 7 and 8, respectively. Recurring themes were grouped to facilitate comparison 195 
with findings arising from the literature review. 196 
 197 
Support of an opt-out consent strategy 198 
Rationale for supporting opt-out research 199 
 The most cited reason for supporting opt-out consent was appreciation that research 200 
advances medical knowledge, fostering understanding of disease (Table 7). Participants 201 
mentioned they would participate in an opt-out study to benefit future patients (Table 7). 202 
Improving practice for future generations, along with gratefulness to past research subjects, the 203 
hospital and the NHS, made presupposed consent in research acceptable to participants, who 204 
likened it to a form of public duty (Table 7).  205 
 206 
Trust for researchers and research institutions 207 
 Upon probing, all participants agreed having great trust in the medical institution attended 208 
for treatment. Crucially, participants confided in researchers, hence would likely engage if an opt-209 
out study were to be established (Table 7). Participants were certain their care standard would be 210 
unaltered in spite of any decision to opt-out from a future study (Table 7).  211 
 212 
Safeguards- opportunity to opt-out 213 
Participants were unambiguous that their participation in opt-out research would be 214 
dependent on the key condition it were clear they could opt-out, and at any moment (Table 7).  215 
 216 
Harassing research requests 217 
Discussing research in general, participants were fearful of being “bombarded” or harassed 218 
by researchers’ recruitment requests. Participants were apprehensive researchers could insistently 219 
request participation or do so at inopportune moments, as had happened to many in the past 220 
(Table 7). Specific concern was voiced on receiving unsolicited phone calls and emails by 221 
researchers (Table 7). Participants felt reassured when explained that an opt-out observational 222 
study of their medical records would not entail getting contacted other than for initial opting-out, 223 
constituting a strong basis of preference for opt-out consent.  224 
 225 
Concerns about an opt-out consent strategy 226 
Data protection and privacy 227 
 Participants manifested worry for the loss of privacy that an opt-out consent system could 228 
entail, presupposing that data mishandling or corruption would be inevitable (Table 8). Whilst they 229 
agreed this would make them question their participation, not necessarily it would discourage 230 
them to opt-out.    231 
 232 
Sharing information with pharmaceutical companies 233 
 Participants were apprehensive the data obtained from opt-out research could be shared 234 
with third parties, chiefly pharmaceutical companies. Concern was raised that these have 235 
questionable data handling methods and ineffective privacy policies (Table 8).  However, 236 
participants also acknowledged the existence of a dilemma, constituted on one part by the 237 
scepticism of the public against pharmaceutical companies, and on the other by the benefits of 238 
conceding data to these, including monetary compensation supporting research and the chance of 239 
contributing to the development of new drugs (Table 8). 240 
 241 
Inappropriate use of data by other third parties 242 
 Patient’s scepticism on the sharing of opt-out research data with third parties extends to 243 
commercial entities other than the pharmaceutical industry, particularly mortgage and insurance 244 
companies. Participants recognised that if sensitive data were shared or leaked to these, 245 
discrimination towards particular groups could arise (Table 8).  246 
 247 
Patients’ comprehension of opt-out consent 248 
As previously mentioned, most participants had no prior knowledge of opt-out consent, 249 
and concern was voiced that other patients might not comprehend the functioning of an opt-out 250 
system at first presentation. Allusions to the public’s functional illiteracy were made, and concern 251 
was voiced on the understanding of at-risk groups of patients (Table 8).  Participants underlined 252 
the need for clear and concise information throughout (Table 8). This would increase the 253 
likelihood that they read and understood the introductory statement to an opt-out study. 254 
Participants also suggested the use of descriptive illustrations, informative posters, text messages, 255 
and of digital media to elucidate opting-out (Table 8). 256 
 257 
Desire for more information 258 
 Throughout the focus group, participants underlined the desire for additional information 259 
on how their data would be used and what research would be performed in an opt-out study. 260 
Many supported that explaining patients the usefulness of their data through anecdotes could 261 
provide them with greater incentives to participate in research, bolstering presupposed consent 262 
(Table 8). 263 
 264 
Patient-consumer panel  265 
 The participants consulted as part of the patient-consumer panel reiterated and 266 
reinforced the focus group findings supporting opt-out systems. Similarly to the focus group 267 
held, particular emphasis was placed upon the need for detailed yet clear information given 268 
to prospective participants in research presupposing consent. The use of forms of 269 
communication alternative to simple text, including images, posters, and digital media, was 270 
discussed in detail and supported by participants.  271 
 272 
Institutional experience of opt-out consent 273 
Opt-out consent for collection of data by the designated clinical care team has been 274 
an integral part of data capture for patients with upper gastro-intestinal cancer in our 275 
institution for one year (35, 36). Combining ethical approval and support from a major 276 
patient representative body as part of the consultation process, more than 100 consecutive 277 
patients have been successfully enrolled within this system without any withdrawal of 278 
consent to date. Data is explicitly for use by the clinical team and transfer to third parties, 279 
including pharmaceuticals, is not permitted. Patient feedback has been extremely positive 280 
and many also choose to enrol in further research projects for which study-specific consent 281 
is obtained. 282 
 283 
DISCUSSION 284 
Combining the recurring themes from our focus group with our synthesis of existing 285 
literature and institutional experience reveals the public’s willingness to participate in research 286 
recruiting on the basis of opt-out consent. This is motivated by the will to advance medical 287 
knowledge and to benefit future generations. A novel finding from the focus group discussion is 288 
support of opt-out recruitment as a form of public duty.  This perception of opt-out consent 289 
accords with proposed theories that research should be regarded a moral imperative.(37, 38) 290 
Most importantly, it denotes underlying propensity of the public to join research, fundamental to 291 
the presupposed consent of opt-out systems. 292 
 Whilst the advantages of opt-out consent systems were recognised in some papers 293 
analysed, the literature and our focus group showed participants were generally unaware of such. 294 
Only one reviewed paper noted that opt-out consent can eliminate the necessity of repeated 295 
consents for singular studies.(25) This is particularly relevant considering the apprehension for 296 
redundant recruitment requests uncovered during our focus group. From the researchers’ 297 
viewpoint, only three studies reported appreciation of opt-out systems’ organisational, economic 298 
and time effectiveness in respect to other consent methods.(25-27). Though discussed in the 299 
introductory presentation, this was not recognized in our focus group, where only one participant 300 
acknowledged the advantage of limiting selection bias. This reveals that effective education of the 301 
public with regards to the benefits and conveniences of opt-out consent is essential for its 302 
support. 303 
 Albeit focus group participants were supportive of opt-out systems, they were so at the 304 
specific condition that opting-out is ensured possible, and at all times. This finding is echoed in 305 
four papers included in the review.(23, 25, 27, 33) The request for this safeguard to autonomy 306 
denotes the fundamentality of independent choice to participants.(23, 27, 30, 32, 33) 307 
Notwithstanding these requests, focus group and literature participants failed to mention existing 308 
safeguards currently present in medical research, including research ethics committees, NHS and 309 
hospital governance protocols.(34, 39) This suggests participants’ safeguarding requests to be 310 
secondary to their unawareness of pre-existent protections, additionally implying the need for 311 
greater education of the public. Overall, the trust avowed to researchers and institutions in the 312 
literature and our focus group outlines the basis for support of opt-out research, however 313 
elucidating present safeguards should provide further reassurance to participants, bolstering 314 
support of opt-out. (22-24, 28, 30-32) 315 
Two main concerns on opt-out consent were uncovered, many shared between the focus 316 
group participants and the audited literature: (1) data protection and (2) third parties’ use of data. 317 
Firstly, participants presupposed that breaches in privacy are unavoidable, manifesting scepticism 318 
on the security measures currently present – though better education about the process of data 319 
anonymization should also better inform potential participants.(30, 31, 33) Secondly, participants 320 
found the sharing of their data with commercial companies- chiefly the pharmaceutical industry- 321 
questionable, even though they could also identify benefits in terms of new drug 322 
development.(28, 32, 33) This delicate equilibrium underlying acceptability of commercial data 323 
sharing should be subject of future studies, elucidating the precise circumstances warranting 324 
approval by the public. With respect to use of data by companies such as banks, mortgage and 325 
insurance companies, it is crucial to inform participants that such sharing and use by third party 326 
companies is prohibited, both by data privacy legislation (including GDPR) and by the terms on 327 
which studies are authorised by ethical committees.  328 
 An overarching theme arising in both our focus group and the analysed literature is the 329 
necessity for additional public information regarding opt-out research. This finding was also 330 
confirmed by the discussion held in the patient-consumer panel consulted. Participants in our 331 
group and nine previous reports voiced concerns on receiving insufficient information regarding 332 
opt-out consent, tampering with their independent choice of participation.(22, 26-29, 31-34) 333 
Participants requested elucidations on the nature of the research performed and on the access to 334 
their data. Indeed, participants’ unawareness of the benefits of presupposed consent and of the 335 
safeguards existent in research suggest that current public knowledge of opt-out research is 336 
inadequate. To promote the public’s perception of opt-out consent, any information supplied 337 
should thus be easily accessible to all patient groups. Alternative forms of communication, 338 
including text messages and digital media such as videos, were also suggested by participants. 339 
Moreover, the strategic potential of publicity in gaining the approval of a wider public for opt-out 340 
recruitment systems should not be undervalued. 341 
 We made every effort to include all relevant publications available to date through various 342 
sources.  In addition, clearly defined inclusion criteria were specified a priori. Nonetheless, our 343 
study is limited in that we only conducted one focus group comprised of oncological patients and 344 
family. Due to the participants’ background and recruitment by invitation, it is possible individuals 345 
highly engaged and favouring research were overrepresented. Moreover, some participants were 346 
previously acquainted with the research nurse conducting the group, possibly introducing 347 
response bias through social desirability.  We tried to overcome these limitations by validating our 348 
findings consulting an experienced research consumer panel. No new views were identified 349 
through these discussions and hence we are confident that we reached a point of saturation (20). 350 
Our institutional experience of opt-out consent for use of data by clinical teams has also been very 351 
positive, affirming the principles outlined above in real world terms. However, it needs to be 352 
highlighted that all our qualitative work has focused on those affected by cancer and it is possible 353 
that this may influence their attitude in terms of health and research. Future studies should be 354 
done in other chronic disease settings.  355 
The findings of this study should also be considered in light of the recent changes to data 356 
privacy laws in Europe.  Of the papers reviewed, those performed in the UK were carried out at a 357 
time when the Data Protection Act 1998 was the applicable law, whilst the Canadian study falls 358 
under Canadian data protection laws, recognised by the EU as having general equivalence of effect 359 
to European Data Protection law and providing an adequate degree of protection. The American 360 
studies are subject to a data protection legislative framework generally less stringent than the 361 
former two. Nonetheless, all three systems allow- or allowed- valid consent to be given by opt-out 362 
methods.  363 
The legal acceptability of opt-out as valid consent for processing personal data has 364 
changed substantially in Europe with the General Data Protection Regulation (GDPR) coming into 365 
force in May 2018.(40) Overall, GDPR raised the standard for consent, generally deeming opt-out 366 
to be no longer sufficient in showing valid consent for processing personal data. Rather, GDPR 367 
requires consent to be explicit, freely given, specific, informed and unambiguous, with opt-in 368 
meeting such requirements.(40) 369 
Nonetheless, it should be noted that consent is not an absolute requirement for processing 370 
personal data under GDPR. Indeed, this is permitted if justified by one of six lawful bases, all 371 
equivalent to consent in importance.(40) Hence, if consent is chosen as the basis for processing of 372 
health data in Europe, such must be on an opt-in basis.  However, if the justification for processing 373 
data falls under another of the six bases outlined by GDPR, processing patient data may still be 374 
lawful (for instance, using data to protect valid interests of the patient).  375 
Thus, it is predicted that opt-out consent is to be superseded by opt-in consent for 376 
observational research in Europe. This is only applicable if there are no other lawful bases under 377 
which the data is being processed. In observational studies, researchers may consider either 378 
utilising one of the alternative bases- rather than relying on consent- or fully anonymising 379 
information, consequently abstracting it from the ambit of GDPR altogether. Any such decision will 380 
require greater scrutiny prior to acceptance as part of a research proposal. 381 
 382 
CONCLUSIONS 383 
 Consistently with the literature available, participants in our focus group were positive 384 
about the use of opt-out consent in observational research. Participants understood opt-out 385 
consent’s benefits to scientific knowledge and future generations, also appreciating its 386 
advantageousness to researchers and to participants themselves. Key concerns which emerged 387 
focussed on privacy and the use of data from opt-out research by third parties. There is also an 388 
irrefutable need for exhaustive yet accessible education and information on opt-out consent. 389 
Improving education of the public regarding opt-out consent is likely to remove the perceived 390 
barriers to this consent methodology, augmenting public trust whilst curbing misbeliefs. This, in 391 
turn, could decrease selection bias in research, empowering more equitable care for all patients. A 392 
potential impediment, however, is represented by the coming into force of the General Data 393 
Protection Regulation in Europe.   394 
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Figure 1. PRISMA flow chart of literature review. 524 
 525 
  526 
Table 1. Focus group interview questions. 527 
Part 1  
Patients' involvement and 
understanding of medical 
research 
What is your understanding of medical research? 
Have you or someone you know ever been approached to 
participate in medical research? 
Have you/would you participate in medical research? 
Do you know what an “opt-out” system is? 
Part 2 Presentation on selection bias and opt-out consent 
Patients' views on opt-out 
consent 
How would you feel if an "opt-out" system were applied to 
medical research? 
Would you participate in an “opt-out” medical study? 
How should we inform patients about our "opt-out" system? 
Who should support & counsel patients who have questions? 
How would you feel if your anonymized data were shared with 
third parties? 
 528 
  529 
Table 2. Summary of existing literature audited. 530 
Author Region Method of data collection 
Participants 
(number) 
Botkin et al. (27) USA Focus groups 131 
Brothers et al. (23) USA Telephonic survey 1022 
Brothers et al. (22) USA In person survey 237 
Brothers et al. (24) USA Semi-structured interviews 84 
Damschroder et al. (28) USA Telephonic survey and deliberation session 513 
Fernandes et al. (29) USA In person survey 166 
Kass et al. (30) USA 
Single structured interview (telephonic/in 
person) 
602 
Lewis et al. (25) UK Focus groups and online survey 1181 
Simon et al. (26) USA Focus groups and telephonic survey 799 
Spencer et al. (31) UK Focus groups and interviews 40 
Stevenson et al. (32) UK Focus groups and interviews 57 
Taylor et al. (33)  UK Focus groups and survey 28 
Willison et al. (34) Canada 
Semi-structured interviews and structured, 
fixed response survey 
123 
 531 
 532 
  533 
Table 3. Themes supportive of opt-out consent identified in existing literature. Blue cells indicate themes also identified in the focus group 
interview held. 
Study Rationale for supporting opt-out research Trust Convenience Presence of safeguards 
  
Research 
advances 
medical 
knowledge 
Research 
benefits 
others 
Research 
benefits 
self/family 
Research 
benefits 
other people 
with same 
disease 
Trust 
researchers
/research 
institution 
Not being 
repeatedly 
asked for 
consent 
More 
cost/ 
time 
effective 
As long as 
opting-out 
is possible 
As long as 
records are 
anonymous 
As long as an 
independent 
"watchdog” 
exists 
(27) ✓ ✓     ✓ ✓  ✓ 
(23)         ✓     ✓ ✓   
(22) ✓ ✓ ✓ ✓ ✓      
(24)   ✓ ✓ ✓ ✓           
(28) ✓    ✓      
(29) ✓                   
(30) ✓    ✓    ✓  
(25) ✓         ✓ ✓ ✓     
(26) ✓ ✓     ✓    
(31) ✓       ✓           
(32) ✓    ✓    ✓  
(33)   ✓           ✓   ✓ 
(34) ✓ ✓         
 
  
Table 4. Themes of concern over opt-out consent identified in existing literature. Blue cells indicate themes also identified in the focus group 
interview held. 
Study Data protection Third parties and inappropriate use of data Information and ability to opt-out 
  
Concern 
for 
privacy 
Sceptical 
security 
is 
sufficient 
Commercial 
use of data 
(drug 
companies) 
Inappropriate 
use by third 
parties 
(insurances, 
banks) 
Data basis for 
discrimination 
Desire for 
more 
information/
explanations 
Initial 
informative 
letter may not be 
read/understood 
Difficulty in 
indicating will 
to opt-out 
Passive 
form of 
consent 
(27) ✓   ✓  ✓    
(23)                   
(22) ✓     ✓    
(24) ✓                 
(28) ✓  ✓   ✓    
(29) ✓         ✓ ✓ ✓   
(30) ✓ ✓   ✓     
(25)                   
(26) ✓   ✓  ✓ ✓  ✓ 
(31) ✓ ✓   ✓   ✓       
(32) ✓  ✓ ✓  ✓ ✓   
(33) ✓ ✓ ✓ ✓ ✓ ✓ ✓     
(34)    ✓  ✓    
 
  
Table 5. Demographics of focus group participants obtained via paper survey.  
  N=13 
Age (%) 
Less than 30 0 (0) 
30-39 1 (10) 
40-49 3 (30) 
50-59 1 (10) 
60-69 5 (50) 
70 or over 3 (30) 
Self-defined ethnicity (%)  
White British 10 (77) 
White Irish 2 (15) 
Ashkenazi Jewish 1 (8) 
Educational level (%) 
No qualifications 3 (30) 
Qualifications below degree level 6 (60) 
Degree or higher 4 (40) 
Relation to Guy's Hospital (%) 
Patient 10 (77) 
Partner 3 (23) 
Family member 0 (0) 
Other carer 0 (0) 
If a patient, reason for attending Guy's Hospital (%) 
Medical reason other than cancer 0 (0) 
At risk of developing cancer 1 (10) 
Cancer diagnosis 9 (90) 
Cancer type (%) 
Bladder 1 (10) 
Prostate 5 (50) 
Testicular 1 (10) 
Breast 2 (20) 
Lung 1 (10) 
Employment status (%) 
Unemployed 3 (23) 
Retired 6 (46) 
Full-time 4 (31) 
Part-time 0 (0) 
Sick-leave 0 (0) 
Distance from hospital (%) 
<5 miles 5 (38) 
5-10 miles 2 (15) 
10-15 miles 3 (23) 
15+ miles 3 (23) 
 
  
Table 6. Supporting quotations from focus group participants approving opt-out consenting. 
Participant 
identifier 
Quotation 
Patient #9 "I’m a big believer of the opt-out system, it makes total sense to me." 
Patient #1 "I definitely believe in an opt-out system." 
Patient #3 "[An opt-out system] wouldn’t bother me." 
Patient #5 "In the principle of an opt-out system I’m in favour of." 
Partner #2 "It wouldn’t be a problem!" 
Patient #4 
"It’s fine, as long as it’s crystal clear you are given the opportunity to 
opt out." 
 
  
Table 7. Representative statements supporting an opt-out consent strategy.  
Rationale for supporting opt out research 
Advancing 
medical 
knowledge 
 
I think research is useful to understanding what happens in the 
body and how diseases develop, and that in turn can be used to 
develop treatments. That’s why I’d do it.  
Benefitting 
future 
generations 
I’d participate for my children, grandchildren, any children. 
For the next generation, that’s why I’d do it. 
Gratefulness 
to past 
participants 
I feel very strongly that I am standing on the shoulders of other people 
who developed and supported research, medicine, cures up to this point. 
My job is to continue this. 
Trust for researchers and research institutions 
Participation 
and trust in 
researchers 
We have great trust in you, we do, that's why we wouldn’t drop out. 
Participation 
and care 
standards 
Interviewer:  Do you think you’d have a different level of care if you didn’t 
take part in an opt-out study?  
Patient #5: No, not at all 
All: shaking heads 
Safeguards- opportunity to opt-out 
Safeguard of 
clear opt-out 
choice 
As long as it’s clear you are given the opportunity to opt out, it’s fine. 
If you got the option to opt-out and it’s clear, wouldn’t bother me. 
Harassing research requests 
Concern for 
harassment 
resolved with 
opt-out 
You always think you’re going to get harassed, you need something to 
make that clear, that you’re not going to be inundated with calls, emails… 
It should be made clear and honest that you’re not going to get 
contacted and anything like that, even when you’re in. You want to make 
it clear to people that staying in doesn’t mean you’re going to get 
bombarded. 
 
 
  
Table 8. Representative statements of concerns on an opt-out consent strategy.  
Data protection and privacy 
Inevitability of 
data 
corruption 
I realize that there is always a risk that data is leaked. …  I think it’s 
about trust, we live in that era… is your stuff safe? I don’t suppose it’s 
safe no matter where it is so straight away I’m on the defence. 
Knowledge of 
safeguards to 
privacy 
There are laws about this kind of information. … I’m sure that none of 
them are perfect, but there is still value in having some guards on it. And 
I guess that’s one thing that matters, assuming that no system is ever 
perfect; have we put safeguards in there? … Part of it is how do we 
make sure that we know when breaches happen and how can we 
control that. 
Sharing information with pharmaceutical companies 
Third parties 
and data 
I am really happy to share information and data but I don’t necessarily 
want drug companies to use my data, because I think they are deeply 
dodgy in how the deal with data. 
Dilemma of 
sharing data 
with 
pharmaceutical 
companies 
The problem is that pharmaceutical companies do genuinely do useful 
research, so there’s a real dilemma here. 
You need a data set to say that this is a drug that is worthwhile for drug 
companies to make, that's why we need to give data to drug companies. 
Inappropriate use of data by other third parties 
Discrimination 
by 
inappropriate 
data use  
I think there are patient concerns around insurances, mortgages and 
other things, about them discriminating patients with data. 
I’d actually think that for lots of people who want to get a mortgage or a 
loan or health insurance this data would really need to be protected. 
Patients’ comprehension of opt-out consent 
Patients 
unable to 
understand 
opt-out 
paperwork 
It must be very simple because people won’t read it if it’s a lot of text. It’s 
going to be quite difficult to get the right balance between information 
and access, as they say the reading age of the UK is a 9-year-old, so a lot 
of patients won’t be able to even understand complex texts. 
Especially for elderly patients, or patients who haven’t been in the UK 
that long, come from a different culture: there are all sorts of reasons 
because people might not get it.  
Clarity of 
information 
given  
It’s about making people understand: educating, understanding and 
being clear and concise about it. 
Use of digital 
media for 
information 
Does everyone here get a text message before their appointment? There 
could be a link on the bottom of that, so when you press that link on your 
phone it goes straight to a video. 
Desire for more information 
Informing 
patients 
provides 
incentive to 
participation 
There’s also a story to be told like: “These are the diseases we figured 
how to treat through data”. … It’s a story to be told, it’s not just 
someone in a lab experimenting and sometimes getting it right… … 
There’s a story about it which is more than information, it’s about sense-
making for people: “This is why data matters, this is why you should be 
thoughtful about your data, and this is also why you might want to 
consider not opting-out.” 
It’s quite important: how do you keep people giving their data? Making 
them feel proud about what they’ve done. 
 
 
